A. B. Payne

发表

Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017.

J. Mehal, W. Hooper, L. Richardson, 2020, Annals of emergency medicine.

Exercise capacity and clinical outcomes in adults followed in the Cooperative Study of Sickle Cell Disease (CSSCD)

A. Payne, S. Badawy, M. Rodeghier, 2018, European journal of haematology.

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity

W. Hooper, C. Miller, J. Soucie, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages — United States, January 2022–May 2023

Samuel S. Shepard, D. MacCannell, Nicholas A. Kovacs, 2023, MMWR. Morbidity and mortality weekly report.

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2

Manish M Patel, A. Randolph, I. Harwayne-Gidansky, 2021, JAMA network open.

Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease.

M. DeBaun, S. Ofori-Acquah, W. Hooper, 2012, Blood.

cell disease reduced incidence of acute chest syndrome among children with sickle Heme oxygenase-1 gene promoter polymorphism is associated with

M. DeBaun, S. Ofori-Acquah, W. Hooper, 2013 .

High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites.

H. Austin, W. Hooper, C. Miller, 2014, Ethnicity & disease.

Low forced expiratory volume is associated with earlier death in sickle cell anemia.

M. DeBaun, R. Strunk, A. Kassim, 2014, Blood.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, American Journal of Transplantation.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, MMWR. Morbidity and mortality weekly report.

Stability of specimens for use in the Centers for Disease Control and Prevention assays for factor VIII and IX inhibitors

C. Miller, C. Bean, B. Boylan, 2022, Research and Practice in Thrombosis and Haemostasis.

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab

C. Miller, C. Bean, B. Boylan, 2020, International Journal of Laboratory Hematology.

Evaluation of pre‐analytic heat treatment protocol used in the CDC Nijmegen‐Bethesda assay for heat inactivation of extended half‐life haemophilia treatment products

C. Miller, C. Bean, D. Ellingsen, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen‐Bethesda assay for factor VIII inhibitors

C. Bean, C. Miller, A. Payne, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons — 29 U.S. Jurisdictions, May 22–September 3, 2022

Matthew M. Cole, Elizabeth A Torrone, E. Banerjee, 2022, MMWR. Morbidity and mortality weekly report.

Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022

Matthew M. Cole, I. Spicknall, A. Gundlapalli, 2022, MMWR. Morbidity and mortality weekly report.

Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3, 2022

Elizabeth B White, I. Spicknall, A. Gundlapalli, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023

R. Link-Gelles, A. Fleischauer, Heather M. Scobie, 2023, MMWR. Morbidity and mortality weekly report.

Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases

N. Dowling, J. Griffin, F. España, 2017, Research and practice in thrombosis and haemostasis.

Acute chest syndrome is associated with single nucleotide polymorphism‐defined beta globin cluster haplotype in children with sickle cell anaemia

M. DeBaun, J. Keefer, W. Hooper, 2013, British journal of haematology.

Mutation analysis of a cohort of US patients with hemophilia B

W. Hooper, C. Miller, A. Payne, 2014, American journal of hematology.

Magnetic resonance angiography‐defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose‐6‐phosphate dehydrogenase mutation in children with sickle cell anaemia

Bruce A. Vendt, R. McKinstry, M. DeBaun, 2012, British journal of haematology.

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States

C. Kempton, A. Neff, D. Brettler, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

COVID-19 and Sickle Cell Disease–Related Deaths Reported in the United States

M. Hulihan, L. Schieve, W. Hooper, 2022, Public health reports.

Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020

L. Schieve, G. Peacock, J. Panepinto, 2020, Emerging infectious diseases.

Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.

A. Payne, S. Badawy, A. B. Payne, 2019, Blood advances.